Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPR-6023021 in advanced solid tumors with bone metastases
NCT07249892Phase 2Not yet recruiting
- Sponsor
- Chengdu Syncor Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Alpha Emitters, Beta Emitters
- Countries
- 1
01
Overview
A Phase 2 trial of BPR-6023021 in solid tumor, bone metastases, sponsored by Chengdu Syncor Pharmaceutical. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
BPR-6023021
03
Conditions
solid tumorbone metastases
Beyond the preview
Go deeper on NCT07249892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249892.